Repetitive transcranial magnetic stimulation improves cognition, depression, and walking ability in patients with Parkinson's disease: a meta-analysis.
{"title":"Repetitive transcranial magnetic stimulation improves cognition, depression, and walking ability in patients with Parkinson's disease: a meta-analysis.","authors":"Mingchen Wang, Wenyu Zhang, Wanli Zang","doi":"10.1186/s12883-024-03990-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) on cognitive function, depression, and walking ability in patients with Parkinson's disease.</p><p><strong>Methods: </strong>A comprehensive search was conducted in PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), VIP Database, and Wanfang Database. Randomized controlled trials (RCTs) on rTMS treatment in Parkinson's disease patients were retrieved, covering the period from the inception of each database to July 2024. The quality of the included studies was assessed using the Cochrane risk of bias tool. Two researchers independently screened the literature, extracted data, and assessed the risk of bias in the studies. Data synthesis and analysis were performed using RevMan 5.4 and Stata 17.0 software.</p><p><strong>Results: </strong>A total of 15 studies were included. The meta-analysis revealed that rTMS significantly improved the MOCA score (MD = 2.98, 95% CI 2.08, 3.88, P = 0.000), TUGT score (SMD=-0.72, 95% CI -1.43, 0.00, P = 0.048), FOG-Q score (SMD=-0.54, 95% CI -0.97, -0.11, P = 0.01), and UPDRS-III score (SMD=-0.66, 95% CI -0.84, -0.47, P = 0.000) in Parkinson's disease patients, and also alleviated depressive symptoms as measured by the HAMD (SMD=-0.43, 95% CI -0.72, -0.13, P = 0.004).</p><p><strong>Conclusions: </strong>rTMS can improve cognitive function, depressive symptoms, and walking ability in patients with Parkinson's disease.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"24 1","pages":"490"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668114/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12883-024-03990-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) on cognitive function, depression, and walking ability in patients with Parkinson's disease.
Methods: A comprehensive search was conducted in PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), VIP Database, and Wanfang Database. Randomized controlled trials (RCTs) on rTMS treatment in Parkinson's disease patients were retrieved, covering the period from the inception of each database to July 2024. The quality of the included studies was assessed using the Cochrane risk of bias tool. Two researchers independently screened the literature, extracted data, and assessed the risk of bias in the studies. Data synthesis and analysis were performed using RevMan 5.4 and Stata 17.0 software.
Results: A total of 15 studies were included. The meta-analysis revealed that rTMS significantly improved the MOCA score (MD = 2.98, 95% CI 2.08, 3.88, P = 0.000), TUGT score (SMD=-0.72, 95% CI -1.43, 0.00, P = 0.048), FOG-Q score (SMD=-0.54, 95% CI -0.97, -0.11, P = 0.01), and UPDRS-III score (SMD=-0.66, 95% CI -0.84, -0.47, P = 0.000) in Parkinson's disease patients, and also alleviated depressive symptoms as measured by the HAMD (SMD=-0.43, 95% CI -0.72, -0.13, P = 0.004).
Conclusions: rTMS can improve cognitive function, depressive symptoms, and walking ability in patients with Parkinson's disease.
目的：探讨重复经颅磁刺激（rTMS）对帕金森病患者认知功能、抑郁和行走能力的影响。方法：综合检索PubMed、Web of Science、Embase、Cochrane Library、中国知网（CNKI）、中国生物医学文献数据库（CBM）、VIP数据库、万方数据库。检索了rTMS治疗帕金森病患者的随机对照试验（rct），涵盖了从每个数据库建立到2024年7月的时间。使用Cochrane偏倚风险工具评估纳入研究的质量。两名研究人员独立筛选文献，提取数据，并评估研究中的偏倚风险。采用RevMan 5.4和Stata 17.0软件进行数据综合分析。结果：共纳入15项研究。meta分析显示，rTMS可显著改善帕金森病患者MOCA评分（MD = 2.98, 95% CI 2.08, 3.88, P = 0.000）、TUGT评分（SMD=-0.72, 95% CI -1.43, 0.00, P = 0.048）、fogg - q评分（SMD=-0.54, 95% CI -0.97, -0.11, P = 0.01）、UPDRS-III评分（SMD=-0.66, 95% CI -0.84, -0.47, P = 0.000），并可缓解HAMD测量的抑郁症状（SMD=-0.43, 95% CI -0.72, -0.13, P = 0.004）。结论：rTMS可改善帕金森病患者的认知功能、抑郁症状和行走能力。
期刊介绍：
BMC Neurology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
